CAMBRIDGE, Mass.--(BW HealthWire)--March 29, 2001--Alkermes, Inc. (Nasdaq: ALKS) will be providing a live webcast of a meeting at which management of the company will review the company's business strategy, recent pipeline progress, drug development operations and manufacturing expertise. Alkermes invites investors and the general public to listen to this webcast on April 3, 2001 at 10:00 AM Eastern Time.
The webcast can be accessed by going to the Alkermes website at www.alkermes.com and will be archived and available for replay through the close of business on Friday, April 13, 2001.
Alkermes is a leader in the development of products based on sophisticated drug delivery technologies. The company has several areas of focus, including (i) controlled, sustained release of injectable drugs lasting several days to several weeks, utilizing its ProLease(R) and Medisorb(R) technologies and (ii) the development of pharmaceutical products based on proprietary pulmonary drug delivery technologies utilizing its AIR(TM) technology. Alkermes' first product, Nutropin Depot(TM), was launched in the United States by its partner, Genentech, Inc., in June 2000. Nutropin Depot is a long-acting form of Genentech's recombinant human growth hormone using Alkermes' ProLease technology. In addition to its Cambridge, Massachusetts headquarters, research and manufacturing facilities, Alkermes operates research and manufacturing facilities in Ohio and a medical affairs office in Cambridge, England.
CONTACT:
Investor Relations:
Alkermes, Inc.
Rebecca Peterson
Director, Investor Relations
(617) 583-6378
or
Media Relations:
Burns McClellan
Justin Jackson, (212) 213-0006